PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial

Authors :: Paul B. Chapman
Rebecca Lee
K. B. Kim
K. B. Nolop
Madeleine Duvic
Grant A. McArthur
A. Ribas
Keith T. Flaherty
J. A. Sosman
Mario E. Lacouture
Source :: Journal of Clinical Oncology. 28:8592-8592
Publication Year :: 2010
Publisher :: American Society of Clinical Oncology (ASCO), 2010.
Abstract: 8592 Background: Tumor regressions have been observed in a significant proportion of advanced melanoma patients treated with PLX4032 (RG7204), in a phase I trial with BRAF V600E mutated tumors. Tre...

Subjects :: BRAF V600E
Cancer Research
Pathology
medicine.medical_specialty
Oncology
business.industry
Mutant
medicine
Cancer research
business
neoplasms
Advanced melanoma

Tools